Advances in Motion

Skip to content

Posts by Vivek Naranbhai, MBchB, PhD, DPhil

  • Vivek Naranbhai, MBchB, PhD, DPhil, and colleagues found in an analysis of prospective data that COVID-19 vaccines are well tolerated in patients with cancer and most recipients are likely to be protected against severe disease, although non-mRNA vaccines and some therapies may impair responses.

    Oncology

    Journal

Biography

Vivek Naranbhai, MBchB, PhD, DPhil, is an oncologist in the Mass General Cancer Center and instructor in medicine at Harvard Medical School.

View full profile

Mass General Brigham Cancer Institute

Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.

Resource links